On June 17, 2015 Medivation and Astellas reported that the first patients have been enrolled in TRUMPET (Treatment Registry for Outcomes in CRPC Patie nts), a prospective observational patient registry designed to better understand the unique needs and treatment patterns for patients with castration-resistant prostate cancer (CRPC) (Press release, Medivation, JUN 17, 2015, View Source [SID:1234505447]). The registry will enroll and evaluate 2,000 patients diagnosed with CRPC from urology and oncology sites across the United States. The study will also collect data from the primary caregivers of patients, including spouses, family members and/or friends.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"While there have been many treatment advances in prostate cancer over the past few years, there is still a great deal for us to learn. The insights from TRUMPET can directly impact our research and increase our understanding of important treatment considerations," said Jeffrey Bloss, M.D., senior vice president, Astellas Pharma Global Development, Inc. "This registry provides an important building block to support our commitment to providing effective, evidence-based cancer care for patients and their caregivers."
TRUMPET will follow patients with CRPC and participating caregivers for up to six years to gather information about the management of the disease, including patterns of care, treatment decisions and settings, and physician referral patterns. The registry will also track information about patient health-related quality of life outcomes, work productivity and treatment satisfaction, as well as caregiver health-related quality of life outcomes associated with managing a patient with CRPC.
"As a direct result of advances in therapies available to treat patients with CRPC, treatment decisions have become more complex than ever," said David F. Penson, M.D., M.P.H., chair, department of urologic surgery, Vanderbilt University Medical Center. "TRUMPET will expand our scientific understanding of CRPC to help healthcare professionals, patients and their loved ones make more informed decisions about their care."
TRUMPET is currently enrolling eligible patients and their caregivers; the study will be completed in 2020.